Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by AstraZeneca, AbbVie, Gilead Sciences, and Bristol Myers Squibb.The next frontier […]
